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Results: In comparison to control MCF7 cells, jadomycins G, DNV, B and
N were equally toxic to ABCB1-overexpressing MCF7 cells; jadomycins DNV,
SPhG and N were equally toxic ABCC1-overexpressing MCF7 cells; and only
jadomycin N was equally toxic to ABCG2-overexpressing MCF7 cells. None
of the jadomycin analogues inhibited the efflux of ABCB1, ABCC1 or ABCG2
probe substrates in transport assays.
Conclusion: The ability of jadomycins to retain cytotoxic activity in the
corresponding drug resistant MCF7 cells stems from their ability to circumvent
interactions with the ABCB1, ABCC1 and ABCG2 drug efflux transporters.
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Background: Multidrug resistance to anticancer drugs is a major cause of
chemotherapy failure in cancer patients. In efforts to find novel approaches to
inhibit proliferation and induce apoptosis in lymphoma cells, we examined in
both Hodgkin and non-Hodgkin lymphoma cell lines, the action of naturally
occurring compound curcumin which is nontoxic and has a variety of
therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and
antiseptic activity.
Methods: Both Hodgkin and non-Hodgkin cells were pre-treated with curcumin
followed by exposure to doxorubicin or vincristine and the effect on cell growth
was determined. Cytotoxic effects and determination of apoptotic attributes
upon curcumin treatment were analyzed using flow cytometry assays.
Results: The current study demonstrates that curcumin has the ability to
decrease cell viability and it is due to its capacity to decrease cell proliferation
by causing cell cycle arrest in G2/M phase, and by inducing apoptotic
cell death. curcumin pre-treatment followed by exposure to doxorubicin or
vincristine increased apoptosis as indicated by annexin V staining. It is shown
that curcumin is much more effective on lymphoma cell lines in compare to
doxorubicin or vincristine.
Conclusion: We have demonstrated that curcumin is an efficient inducer of
apoptosis in lymphoma cell lines, meriting its further evaluation in vivo. The
observed effects combined with the well established pharmacological safety
of curcumin, provides rationale for the potential use of curcumin as a new
therapeutic agent for patients with Hodgkin and non-Hodgkin lymphomas.
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Introduction: The pegylated liposomal doxorubicin (PLD) has been widely
accepted in treatment of various cancers. However, the composition of two
currently marketed PLD nanoparticles differs in structure and composition
of lipids, and their differential effects remain unknown. Macrophages of the
mononuclear phagocyte system are pivotal in determination of PLD clearance
in vivo. The aim of this study was to compare the effect of these two PLDs
on drug uptake, cell viability, morphology and immune function of human
macrophages.
Material and Method: Two PLD nanoparticles were used in this study. The
major difference between Lipo-dox® (PLD-D) and Caelyx® (PLD-H) is that
their phospholipid bilayers are composed of distearoyl phosphatidylcholine
(DSPC) and hydrogenated soybean phosphatidylcholine (HSPC), respectively.
Human CD14+ monocytes were isolated from peripheral blood to prepare
macrophages for this study. Comparative assays included: flow cytometry for
detection of doxorubicin penetration into cells, MTT for cell viability, Trypan blue
exclusion for cell membrane integrity, Liu’s stain for morphologic evaluation,
inactivated yeast co-culture for phagocytosis.
Results and Discussion: The uptake of PLD-H was rapidly detected at 10
min and kept increasing to 4 h followed by a decline thereafter, whereas
that of PLD-D had similar profile with much less doxorubicin fluorescence
detected, indicating a greater amount of doxorubicin retention of PLD-H.
PLD-H, at higher concentration, decreased the viability and impaired cell
membrane integrity of macrophages with an extent greater than PLD-D.
The morphological observation showed a more extensive necrosis in PLD-H-
treated macrophages. The phagocytosis function of macrophage was inhibited
with a greater extent in PLD-H-treated macrophages.
Conclusion: To human macrophages, PLD containing HSPC may cause
greater amount and longer retention of doxorubicin in cells, greater toxicity and
more profound dysfunction than that containing DSPC. Whether this differential
effect correlates to the clinical outcome needs to be extensively investigated
by performing in vivo experiments or clinical trials.
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The p53 tumour suppressor is a major regulator of cell proliferation and death.
In tumours that retain a wild-type (wt) p53, the activity of this protein can be
inhibited by the endogenous negative regulator MDM2. In this case, inhibitors
of p53/MDM2 interaction have been considered promising drugs for cancer
therapy [1,2].
In this work, yeast assays consisting of Saccharomyces cerevisiae cells
co-expressing human wt p53 and MDM2 were used for the screening of
inhibitors of p53/MDM2 interaction. In our experimental approaches in yeast,
inhibitors of p53/MDM2 interaction, such as Nutlin-3A, revert the inhibitory
effect of MDM2 on p53-induced growth inhibition/cell cycle arrest as well as
on p53-dependent transcriptional activity of a reporter gene (described in [3]).
A chemical library of small-molecules inhibitors of tumour cell growth was
tested and the small-molecule LEM1 was identified as inhibitor of p53/MDM2
interaction. The validation of the molecular mechanism of action of LEM1
was carried out in two human tumour cell lines derived from breast cancer
(MCF7) and colon carcinoma (HCT116 p53+/+) by performing gene reporter
assays and by analysis of p53, p21 and Bax protein levels as well as caspase
activation by Western blot. The results obtained confirmed that 10 mM LEM1
treatment stimulated p53-dependent transcriptional activity, led to p53 protein
stabilization, increased p21 and Bax protein levels, and induced caspase-7
activation in human tumour cell lines. Notably, these effects were not observed
in the HCT116 p53−/− derivative cell line.
In conclusion, an efficient yeast-based high-throughput screening strategy was
established to search for inhibitors of p53/MDM2 interaction. Most importantly,
with this approach, LEM1 was discovered as an inhibitor of p53/MDM2
interaction. LEM1 represents a promising small-molecule to be further explored
as anticancer drug and/or as a lead compound toward the synthesis of more
potent and selective inhibitors of p53/MDM2 interaction.
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Introduction: Ewing Sarcoma (ES) is a malignant tumor affecting mainly
children and young adults, arising especially in bone and soft tissue and
characterized by the presence of a chromosomal translocation responsible
for the transcriptional deregulation of target genes such as the membrane
receptor CD99. The origin of ES has long been the focus of intensive research,
however, recently a Mesenchymal Stem Cell (hMSC) origin has been assumed
as the most probable.
Despite prior evidence suggesting a hMSC origin of ES, hMSC from ES
patients have not been sufficiently investigated. Herein, we compared a large
